Identification of L169P mutation in the omega loop of KPC-3 after a short course of ceftazidime/avibactam

1 Iovleva A, Doi Y. Carbapenem-resistant Enterobacteriaceae. Clin Lab Med 2017; 37: 303–15. 2 van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2017; 8: 460–9. 3 Pence MA, Hink T, Burnham C-A. Comparison of chromogenic media for recovery of carbapenemase-producing Enterobacteriaceae (CPE) and evaluation of CPE prevalence at a tertiary care academic medical center. J Clin Microbiol 2015; 53: 663–6. 4 Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2012; 18: 1503–7. 5 Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect 2017; 23: 704–12. 6 Tamma PD, Simner PJ. Phenotypic detection of carbapenemaseproducing organisms from clinical isolates. J Clin Microbiol 2018; 56: e01140-18. 7 Riccobono E, Antonelli A, Pecile P et al. Evaluation of the KPC K-SeT R immunochromatographic assay for the rapid detection of KPC carbapenemase producers from positive blood cultures. J Antimicrob Chemother 2018; 73: 539–40. 8 Sherry N, Howden B. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam—epidemiology, laboratory detection and treatment implications. Expert Rev Anti Infect Ther 2018; 16: 289–306. 9 Gaibani P, Campoli C, Lewis RE et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/ avibactam treatment. J Antimicrob Chemother 2018; 73: 1525–9. 10 Nelson K, Hemarajata P, Sun D et al. Resistance to ceftazidimeavibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob Agents Chemother 2017; 61: e00989-17. 11 Haidar G, Clancy CJ, Shields RK et al. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum b-lactamases. Antimicrob Agents Chemother 2017; 61: e02534-16. 12 Antonelli A, Arena F, Giani T et al. Performance of the BD MAX instrument with Check-Direct CPE real-time PCR for the detection of carbapenemase genes from rectal swabs, in a setting with endemic dissemination of carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis 2016; 86: 30–4. 13 Lomovskaya O, Sun D, Rubio-Aparicio D et al. Vaborbactam: spectrum of b-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61: e01443-17. 14 Compain F, Arthur M. Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the DY substitution in the KPC-2 b-lactamase. Antimicrob Agents Chemother 2017; 61: e00451-17.

[1]  R. Humphries,et al.  Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2 , 2019, The Journal of antimicrobial chemotherapy.

[2]  P. Tamma,et al.  Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates , 2018, Journal of Clinical Microbiology.

[3]  S. Pongolini,et al.  In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment , 2018, The Journal of antimicrobial chemotherapy.

[4]  B. Howden,et al.  Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam – epidemiology, laboratory detection and treatment implications , 2018, Expert review of anti-infective therapy.

[5]  K. Kazmierczak,et al.  Global survey of Klebsiella pneumoniae major porins from ertapenem non‐susceptible isolates lacking carbapenemases , 2018, Journal of medical microbiology.

[6]  G. Rossolini,et al.  Evaluation of the KPC K-SeT® immunochromatographic assay for the rapid detection of KPC carbapenemase producers from positive blood cultures , 2018, Journal of Antimicrobial Chemotherapy.

[7]  Stephania Stump,et al.  Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates , 2017, Antimicrobial Agents and Chemotherapy.

[8]  R. Bonomo,et al.  New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  A. Kasarskis,et al.  Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity , 2017, Antimicrobial Agents and Chemotherapy.

[10]  Alina Iovleva,et al.  Carbapenem-Resistant Enterobacteriaceae. , 2017, Clinics in laboratory medicine.

[11]  D. van Duin,et al.  The global epidemiology of carbapenemase-producing Enterobacteriaceae , 2017, Virulence.

[12]  C. Clancy,et al.  Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases , 2017, Antimicrobial Agents and Chemotherapy.

[13]  B. Kreiswirth,et al.  Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections , 2016, Antimicrobial Agents and Chemotherapy.

[14]  B. Kreiswirth,et al.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  G. Rossolini,et al.  Performance of the BD MAX™ instrument with Check-Direct CPE real-time PCR for the detection of carbapenemase genes from rectal swabs, in a setting with endemic dissemination of carbapenemase-producing Enterobacteriaceae. , 2016, Diagnostic microbiology and infectious disease.

[16]  R. Humphries,et al.  First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate , 2015, Antimicrobial Agents and Chemotherapy.

[17]  N. Iovine,et al.  Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae , 2015, Antimicrobial Agents and Chemotherapy.

[18]  C. Burnham,et al.  Comparison of Chromogenic Media for Recovery of Carbapenemase-Producing Enterobacteriaceae (CPE) and Evaluation of CPE Prevalence at a Tertiary Care Academic Medical Center , 2014, Journal of Clinical Microbiology.